Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Synthekine, Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 4 examiners and 4 art units, so prosecution activity is distributed across four examination assignments.
REDDIG, PETER J is the busiest examiner, with 1 pending matter. The data does not show concentration of multiple pending matters with that examiner, which supports separate tracking and response preparation for each assignment.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDDIG, PETER J | 1 | 58.0% | +40.2% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — |
| 18260688 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | ROONEY, NORA MAUREEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 49d overdue |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 9d overdue |
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | — |
| 18260688 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1643 | 1 |
| 1641 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576329 | METHODS AND COMPOSITIONS FOR USE IN CELL THERAPY OF NEOPLASTIC DISEASE | REDDIG, PETER J | 1646 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18260709 | COMPOSITIONS AND METHODS RELATED TO IL2 RECEPTOR BINDING | DUFFY, BRADLEY | 1643 | §102§103 | Final Rejection | 49d overdue | Pending | Jul 07, 2023 |
| 18260688 | COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING | ROONEY, NORA MAUREEN | 1641 | §103§112Other | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18040260 | CD45 BINDING MOLECULES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 9d overdue | Pending | Feb 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynthekine, Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Peter J Reddig has the most, with 1 of Synthekine, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
